Bank Pictet & Cie Europe AG Sells 360 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Bank Pictet & Cie Europe AG cut its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 12.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,467 shares of the biotechnology company’s stock after selling 360 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Sarepta Therapeutics were worth $300,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in SRPT. MassMutual Private Wealth & Trust FSB grew its position in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares in the last quarter. Sunbelt Securities Inc. grew its position in shares of Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares in the last quarter. Huntington National Bank grew its position in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new position in shares of Sarepta Therapeutics in the fourth quarter valued at $36,000. Finally, Values First Advisors Inc. purchased a new position in shares of Sarepta Therapeutics in the third quarter valued at $59,000. 86.68% of the stock is currently owned by institutional investors.

Insider Activity at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Trading Down 1.4 %

Shares of SRPT stock opened at $107.95 on Friday. The stock has a market capitalization of $10.31 billion, a PE ratio of 86.36 and a beta of 0.75. Sarepta Therapeutics, Inc. has a 1-year low of $102.15 and a 1-year high of $173.25. The business has a 50-day moving average of $119.42 and a 200 day moving average of $124.72. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Analyst Ratings Changes

Several brokerages have recently weighed in on SRPT. Deutsche Bank Aktiengesellschaft began coverage on Sarepta Therapeutics in a research report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price target for the company. Needham & Company LLC restated a “buy” rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research report on Monday, January 27th. HC Wainwright restated a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research note on Thursday. Guggenheim upped their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $176.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.